Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00960557

Acronym

OXi4503

Enrollment

Registered

2009-08-18

Start date

2009-07-31

Completion date

2010-10-31

Last updated

2011-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm Metastasis

Keywords

hepatic tumor burden, liver cancer, liver carcinoma, carcinoma, hepatic cancer, hepatic carcinoma, VDA, Vascular Disrupting Agent

Brief summary

The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

Interventions

DRUGCombretastatin A1 Diphosphate (OXi4503)

OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologically or cytologically confirmed carcinoma. Tumor must be relapsed or refractory to standard therapies, or have no acceptable standard therapy. 2. Measurable disease by RECIST criteria. 3. Subjects must be at least 28 days from other investigational therapy and at least 2 weeks after chemotherapy or radiation therapy. 4. Age 18 years or older. 5. Eastern Cooperative Oncology Group (ECOG) Performance Score of less than 1. 6. Life expectancy of greater than 12 weeks. 7. Hemoglobin greater than 10 g/dL. 8. Adequate hepatic function. 9. Adequate renal function. 10. Adequate bone marrow reserve. 11. Able to maintain potassium, calcium and magnesium levels within normal ranges. 12. Must be able to provide written informed consent. 13. All women of childbearing potential (WOCBP) must have a negative serum pregnancy test. 14. WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication.

Exclusion criteria

1. Uncontrolled CNS metastases. 2. No other active malignancies. 3. Poorly controlled hypertension. 4. Recent history of serious cardiovascular conditions. 5. Recent history of CVA, TIA, or intermittent claudication. 6. Current anticoagulation therapy. 7. History of cardiac arrhythmias. 8. Abnormal ECG findings. 9. Subjects who require concomitant medications which cause QTc prolongation. 10. Major surgery within 30 days of treatment, or minor surgery within 7 days of treatment. 11. Uncontrolled, clinically significant active infection. 12. Subjects who are pregnant or lactating. 13. Subjects with any other intercurrent medical condition. 14. Subjects with a history of solid organ transplant or bone marrow transplant.

Design outcomes

Primary

Measure	Time frame
To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.	6 Months

Secondary

Measure	Time frame
To determine progression-free survival (PFS).	6 Months

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026